Solid Dosage
We supply proven solutions for manufacturing central nervous system drugs, tackling challenges such as containment, intranasal delivery, small-scale R&D, etc
There are many different types of drugs that work on the central nervous system (CNS), including anesthetics, anticonvulsants, antiemetics, anti-Parkinson agents, stimulants, muscle relaxants and sedatives.
As many of these products can cause serious side-effects from occupational exposure, containment is a key aspect to consider during the manufacturing process. As containment experts, we not only offer the largest variety of solutions for contained processing, but also unrivaled experience in identifying the most appropriate solution based on a containment risk analysis.
Delivering medication to the central nervous system remains challenging, which is why the industry continues to look at alternative methods of administration, such as the intranasal route or the use of colloidal drug carriers.
For inhalable versions, homogeneity and stability are key factors. Our dry powder blending, spray drying and particle engineering capabilities ensure that the production of free-flowing, aerodynamic particles at the correct size is achievable at the scale you need.
We also supply proven solutions for solid dispersions for bioavailability enhancement, such as extrusion, spheronization and a complete engineering service from system design to process integration and optimization.
Furthermore, we understand that during early research and development (R&D), the availability of the active ingredient is often limited. As such, there is an absolute requirement for process equipment that is capable of producing just a few hundred grams of finished product to fast-track new drug formulations.
Designed for small-scale and R&D applications, particularly with potent actives, the PharmaConnect®-PLUS — based on the established combination of a single control unit with a diverse range of process modules — is GEA’s modular granulation, extrusion/spheronization and blending system that offers an unbeatable range of process types and capacities, and also integrates with the Flexstream range of fluidized bed processors.
In addition, the ConsiGma® 4.0 platform combines Quality by Design (QbD) principles with DoE to explore and optimize a wide range of process parameters with less product in a shorter time frame.
Отображение 4 из 26
Contained Materials Handling solutions for Primary and Secondary Pharmaceuticals and Healthcare. With extensive experience within the generics sector, supply a wide range of technologies and equipment that improve and enhance the efficiency and performance of Oral Solid Dosage production.
The ConsiGma® DC for direct compression is the latest expansion of GEA's continuous portfolio for cost effective, compact, high yield manufacturing systems. It offers a robust and flexible manufacturing method for a wide range of products.
Continuous Processing is becoming more and more important in the pharmaceutical industry. GEA takes the lead in introducing this innovative technology with ConsiGma® - continuous high-shear granulation and drying lines.
At GEA, we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product lifecycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Изменение климата и растущее население планеты оказывают повышенное давление на энергоемкую пищевую промышленность, чтобы накормить больше людей и при этом не нанести вред планете. Джордж Шеперд, менеджер по глобальной технической устойчивости компании GEA, объясняет, как компания GEA использует свои инженерные ноу-хау, чтобы помочь переработчикам производить продукцию более устойчиво и при этом повысить производительность.
The world's population is growing and with it demand for milk. Dairy is an essential component of many global diets. However, its production can be resource-intensive and impact the environment. GEA’s Christian Müller, Senior Director Sustainability Farm Technologies, sheds light on how technological innovations powered by GEA make milk production more efficient and profitable.
Каждый безопасный для употребления напиток и пищевой продукт — это победа над невидимыми микробными угрозами — борьба, которая ведется в течение уже ста лет разработки и проектирования технологических процессов, отвечающих требованиям гигиенических норм. Обладая более чем 100-летним опытом и уникальными знаниями в области проектирования и гигиенического проектирования, компания GEA устанавливает отраслевые стандарты для технологического оборудования, задачей которого является защита продуктов питания и спасение жизней людей.